• Protocols

• EAY191N4

  OPEN TO ACCRUAL

  Ph2 Randomized Selumetinib, Olaparib or Selumetinib in Patients w/Ovarian and Endometrial Cancer
  
  

• GOG3083

  OPEN TO ACCRUAL

  Ph 3 Trial of Selinexor for Patients w/ p53 Wild Type, Advanced, or Recurrent Endometrial Carcinoma